



IWK Health

Research

5850/5980 University Avenue

PO Box 9700, Halifax

Nova Scotia B3K 6R8

Canada

Tel: 902.470.8888

www.iwk.nshealth.ca

May 21, 2021

RE: World Journal of Gastroenterology Manuscript NO: 64591, Ethical Review/ Approval Requirement

To Whom It May Concern,

This letter serves to certify that the studies listed below were reviewed and approved by the IWK Health Research Ethics Board (REB) with Dr Anthony Otley as the Principal Investigator. The approval letters for these studies only exist in paper copy and due to ongoing COVID-19 Pandemic restrictions in Nova Scotia, Canada, these cannot be obtained from our long-term storage facility.

REB File No.: 3899

Title of Protocol: A Multi-Centre, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in pediatric Subjects with Moderate to Severe Crohn's Disease

Approval Date: 16-APR-2007

End Date: 30-JUN-2010

REB File No.: 2631

Title of Protocol: A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF α Chimeric Monoclonal Antibody (Infliximab, REMICADE[®]) in Pediatric Subjects with Moderate to Severe Crohn's Disease

Approval Date: 26-JAN-2003

End Date: 12-APR-2007

REB File No.: 2163

Title of Protocol: Pediatric IBD Registry (former title: The Pediatric TREAT[™] Registry: A Pediatric Crohn's Therapy, Resource, Evaluation and Assessment Tool Registry)

Approval Date: 18-FEB-2001

End Date: 16-JAN-2017

Sincerely,

Eleanor Fitzpatrick

Co-Chair, Research Ethics Board